SCMOM 2012_NeoStem
NeoStem, Inc. is an emerging technology leader in the fast-developing cell therapy market. Its business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC, with a medically important cell therapy product development program. NeoStem #39;s most clinically advanced therapeutic, AMR-001, is being developed at its Amorcyte subsidiary, which is enrolling patients in a Phase 2 trial for preservation of heart function after a heart attack. Athelos Corporation, also a NeoStem subsidiary, is in early stage clinical exploration of a T-cell therapy for autoimmune conditions. Pre-clinical assets include our VSELTM Technology platform and our mesenchymal stem cell product candidate for regenerative medicine. http://www.neostem.com Presenter: Jonathan Sackner-Bernstein, NeoStem, Inc.From:AllianceRegenMedViews:4 1ratingsTime:14:54More inScience Technology
See the article here:
SCMOM 2012_NeoStem - Video